<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00590278</url>
  </required_header>
  <id_info>
    <org_study_id>1694TR/01</org_study_id>
    <nct_id>NCT00590278</nct_id>
  </id_info>
  <brief_title>A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer</brief_title>
  <acronym>TOMUDEX</acronym>
  <official_title>A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pilot study is designed to investigate the value of Neo-adjuvant Tomudez in combination
      with radiotherapy in patients with inoperable or recurrent rectal cancer in terms of response
      rate and increasing the resectability of initially inoperable rectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>This study will evaluate the value of TOMUDEX in combination with a 'standard' course of pelvic radiotherapy for inoperable/recurrent rectal cancer, in terms of response rate and increasing the resectability rate</measure>
  </primary_outcome>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Inoperable or Recurrent Rectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tomudex</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Haematology</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biochemistry</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of inoperable/recurrent rectal cancer

          -  Age &gt; 18 years

          -  At least 1 measurable lesion should be present

          -  WHO performance score &lt; 2

          -  Life expentancy of at least 12 weeks

          -  Subjects will be considered appropriate to receive systemic chemotherapy and pelvic
             radiotherapy

          -  Documented informed consent to participate in the trial

        Exclusion Criteria:

          -  Previous systemic chemotherapy

          -  Previous radiotherapy to the planned exposure area

          -  Subjects with distant metastases

          -  (a)white blood cell &lt; 4.0x109/L (unless absolute neutrophil count is &gt;2.0x109/L or (b)
             Platelet count &lt; 100x109/L

          -  Serum creatinine above the upper limit of the normal range

          -  (a) Serum bilirubin &gt; 1.25 times the upper limit of the normal range or (b) Asparate
             aminotransferase(AST) or Alanine amiontransferase (ALT) &gt;2.5 times the upper limit of
             the normal range

          -  Any severe concurrent medical condition which would make it undesirable, in the
             clinician's opinion, for the patient to participate in the trial or which would
             jeopardise compliance with the trial period

          -  Pregnancy or breast feeding. Women of childbearing age must use effective
             contraception

          -  Previous or current malignancies at other sites, with the exception of adequately
             treated in-situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of
             the skin

          -  Patient participation in other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tayfun Hancilar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Okmeydani Hospital Istanbul</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <last_update_submitted>January 23, 2008</last_update_submitted>
  <last_update_submitted_qc>January 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Tayfun Hancilar</name_title>
    <organization>AstraZeneca Turkey Clinical Study Information</organization>
  </responsible_party>
  <keyword>Tomudex</keyword>
  <keyword>inoperable rectal cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

